Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 6/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 3/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8767631 | 0.96 | LMNA (0.40) | LMNAFAAHMMP3PTGER4 | |
| SCHEMBL8772426 | 0.88 | TRPA1 (0.41) | TRPA1TRPV1LMNAFAAHNAAA | |
| SCHEMBL8767268 | 0.82 | TRPA1 (0.41) | TRPA1TRPV1LMNAFAAHMMP1 | |
| SCHEMBL8766792 | 0.81 | TRPA1 (0.40) | TRPA1TRPV1LMNAFAAHMMP1 | |
| SCHEMBL8772394 | 0.79 | TRPA1 (0.40) | TRPA1TRPV1LMNAFAAHMMP1 | |
| SCHEMBL8767549 | 0.76 | LMNA (0.39) | LMNAFAAHMMP3 | |
| SCHEMBL8766432 | 0.74 | HTT (0.40) | LMNA | |
| SCHEMBL8552278 | 0.73 | HMOX1 (0.48) | TRPA1LMNA | |
| SCHEMBL8772451 | 0.69 | LMNA (0.40) | LMNA | |
| SCHEMBL8767339 | 0.67 | HTT (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0788478-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-13 | — | — | EP | claimed |
| EP-0788478-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-13 | — | — | EP | disclosed |